Evidence map›Paper›PMID 35098169›Full record

ArticleEuropean urology open science2022

Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy.

Ronald Kool, Gautier Marcq, Surashri Shinde-Jadhav, José João Mansure, Ramy Saleh, Raghu Rajan, Armen Aprikian, Simon Tanguay, Fabio L Cury, Fadi Brimo and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Ronald KoolExperimental Surgery, RI-McGill University Health Centre, McGill University, Montreal, QC, Canada.
Gautier MarcqExperimental Surgery, RI-McGill University Health Centre, McGill University, Montreal, QC, Canada.
Surashri Shinde-JadhavExperimental Surgery, RI-McGill University Health Centre, McGill University, Montreal, QC, Canada.
José João MansureExperimental Surgery, RI-McGill University Health Centre, McGill University, Montreal, QC, Canada.
Ramy SalehDivision of Medical Oncology, McGill University Health Centre, McGill University, Montreal, QC, Canada.
Raghu RajanDivision of Medical Oncology, McGill University Health Centre, McGill University, Montreal, QC, Canada.
Armen AprikianExperimental Surgery, RI-McGill University Health Centre, McGill University, Montreal, QC, Canada.
Simon TanguayExperimental Surgery, RI-McGill University Health Centre, McGill University, Montreal, QC, Canada.
Fabio L CuryExperimental Surgery, RI-McGill University Health Centre, McGill University, Montreal, QC, Canada.
Fadi BrimoDepartment of Pathology, McGill University Health Centre, McGill University, Montreal, QC, Canada.
Luis SouhamiDivision of Radiation Oncology, McGill University Health Centre, McGill University, Montreal, QC, Canada.
Wassim KassoufDivision of Urology, McGill University Health Centre, McGill University, Montreal, QC, Canada.
McGill University Health Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe role of serum lymphocyte-based biomarkers, such as the neutrophil-to-lymphocyte (NLR), lymphocyte-to-monocyte (LMR), and platelet-to-lymphocyte (PLR) ratios, was previously studied in patients with muscle-invasive bladder cancer (MIBC) treated with radical cystectomy but remains underexplored in patients treated with trimodal therapy (TMT).

objectiveTo analyze the impact of serum lymphocyte-based biomarkers on main oncological outcomes after TMT for MIBC. DESIGN SETTING AND

participantsA retrospective study, including 176 patients treated with TMT for nonmetastatic MIBC (cT2-4/cN0-2) between 2001 and 2017 at a tertiary academic center, was conducted.

interventionTMT, consisting of initial maximal transurethral resection of the bladder tumor, followed by radiotherapy with concurrent chemotherapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Clinicopathological characteristics, serum laboratory tests, and imaging reports were collected. NLR, LMR, and PLR were calculated before and at the end of TMT. Dynamic patterns of NLR, LMR, and PLR during TMT were studied. Multivariable regression models were performed to estimate the effect of these biomarkers on complete response (CR) to TMT and survival. RESULTS AND LIMITATIONS: The median age was 75 yr (interquartile range 66-82). Staging was cT2 in 156 (89%) and cN0 in 159 (90%) patients. A pretreatment NLR (pre-NLR) of ≥4.0 was independently associated with lower CR rates (odds ratio 0.32;

conclusionsA high pre-NLR value was independently associated with lower rates of CR and worse survival in MIBC patients undergoing TMT. Prospective validation is needed to implement NLR into clinical practice. PATIENT SUMMARY: In this study, we reported the oncological outcomes of patients with muscle-invasive bladder cancer treated with trimodal therapy. We found that the neutrophil-to-lymphocyte ratio, a cheap and available blood-derived biomarker, was associated with response to trimodal therapy and survival outcomes.

Indexed as

BiomarkersBladder cancerPrognosisRadiotherapy

Identifiers

PMID35098169
PMCPMC8783035
OpenAlexW4200301714

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.